The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Implementing bispecific antibodies in triple-class-exposed multiple myeloma
Ola Landgren, MD, PhD, Sylvester Comprehensive Cancer Center and University of Miami, Miami, FL, discusses key themes from a session he chaired at IMS 2026 on implementing bispecific antibodies for triple-class-exposed patients with relapsed/refractory (R/R) multiple myeloma. He highlights real-world evidence supporting the efficacy and safety of these therapies compared with registrational trials, practical considerations for outpatient step-up dosing and treating higher-risk patients, and differences in access and implementation between the United States and Europe. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Here at the International Myeloma Society meeting in Glasgow, Scotland, I led the session focusing on implementation of bispecific antibodies in the treatment of relapsed refractory multiple myeloma patients that are triple-class exposed. We talked specifically about how the implementation of the step-up dosing in the outpatient setting is being done. We also looked at the real-world data compared to the registrational studies...
Here at the International Myeloma Society meeting in Glasgow, Scotland, I led the session focusing on implementation of bispecific antibodies in the treatment of relapsed refractory multiple myeloma patients that are triple-class exposed. We talked specifically about how the implementation of the step-up dosing in the outpatient setting is being done. We also looked at the real-world data compared to the registrational studies. We looked at a large number of trials, over 10-15 studies in the real-world setting, which were compared to the registrational studies, and I think it’s very reassuring to see that both the efficacy data and the safety data are very consistent in the real-world setting compared to those registrational studies. So that gives us good confidence that these drugs that are not approved actually work in our real patients. I think it’s important to look at patients that have, say, underlying renal insufficiency, or patients that are sicker, they have a higher burden of disease, so they have more adverse features with extramedullary disease and things like that, so we try to shed light on that. The overall session was quite practical and quite clinical, like this meeting, I think, overall, has that flavor, and we try to really communicate the experience that we have from our clinics, so we have representation both from the United States and from the United Kingdom, so we try to give a perspective of the US and Europe, and how there are similarities and differences in barriers, and how we can work together to overcome and make things better for our patients.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
